Joo‐Hee Yi

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 590 citations

A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Stephen M. Eppler, Daniel L. Combs, Timothy D. Henry et al. · Clinical Pharmacology & Therapeutics · 2002 · 266 citations

PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine

Randall Dere, Joo‐Hee Yi, Corinna Lei et al. · Bioanalysis · 2013 · 71 citations

Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer

Manish Gupta, Patricia LoRusso, Bei Wang et al. · The Journal of Clinical Pharmacology · 2011 · 69 citations

Metastatic Breast Cancer, Oncology, Pharmacokinetic Modeling +11

Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine

Montserrat Carrasco‐Triguero, Joo‐Hee Yi, Randall Dere et al. · Bioanalysis · 2013 · 55 citations